SLU‑PP‑332 INJ. 5mg/5mL
65USD
BIO NEXT GEN SLU‑PP‑332 5mg/5mL :
offers a larger format for users who want more flexibility within a structured program. In preclinical studies, SLU‑PP‑332 is linked to ERRα‑driven changes that enhance cellular respiration and endurance‑type muscle adaptations. For insulin resistance, preclinical work reports improvements in selected metabolic readouts (e.g., muscle glucose uptake), though this is not established as a human treatment.
Bio Next Gen™ SLU-PP-332 :
– Pan-ERR Agonist Research Compound
MW: 290.32 Da | C₁₈H₁₄N₂O₂ | CAS: 303760-60-3 | ≥99% LC-MS Purity | Research Use Only (see the generated image above)
Synonyms: SLUPP332, SLU PP 332, CHEMBL4208749, SCHEMBL12937827, BDBM50455424, STK082756
IUPAC Name: 4-hydroxy-N-[(Z)-naphthalen-2-ylmethylideneamino]benzamide
SLU-PP-332 is a potent pan-ERR agonist (ERRα/β/γ) that activates an exercise-mimetic transcriptional program, boosting mitochondrial biogenesis, fatty acid oxidation, and energy expenditure in preclinical models without affecting food intake or activity. Primary research applications include metabolic syndrome, MASLD, muscle endurance, and oxidative capacity studies.
ERRα EC₅₀: 98 nM (highest potency) ERRβ EC₅₀: 230 nM ERRγ EC₅₀: 430 nM Selectivity: >50x vs. ERα/β, other NRs Solubility: DMSO ≥100 mg/mL (344 mM)
Exercise Mimetic: ↑ PGC-1α, NRF1/2, OXPHOS genes; ↑ running endurance +47%
Metabolic Reprogramming: ↓ RER (fat oxidation ↑), ↓ fat mass, ↑ energy expenditure
Muscle Biology: Type IIa oxidative fibers ↑, mitochondrial content ↑, ↓ myostatin
Hepatic Protection: ↓ liver TG, ↑ β-oxidation genes, improved lipid parameters
Preclinical Evidence Summary
ModelDose/RouteKey OutcomesCitationDIO Mice50 mg/kg IP BID x28d↓ Fat mass -18%, ↑ EE +22%, ↓ Liver TG -35%Billon 2024ob/ob Mice50 mg/kg IP BID x15d↓ Adiposity -25%, RER ↓0.15 (fat use ↑)Billon 2023C57BL/6JThermoneutral CLAMS↑ OCR 2.3x, ERR targets ↑4-10xACS Chem BiolC2C12 Myoblasts1-5 μM↑ FAO genes +180%, mtDNA/nDNA +90%BioRxiv 2022
Bio Next Gen™ Structure (see the generated image above)
Dosing & Administration Protocols
**Published Regimens**: • 50 mg/kg IP BID x12-28 days (C57BL/6J, ob/ob) • 25 mg/kg IP QD (chronic models) • Cell: 0.1-5 μM (DMSO stocks) **Formulations** [web:168]: 1. i.p.: DMSO:Tween80:Saline (10:5:85) 2. Oral: DMSO:Corn Oil (10:90) 3. s.c.: DMSO:PEG300:Tween80 (10:40:5) **Storage**: • Powder: -20°C (36 months) • DMSO Stock: -80°C aliquots (single-use) ✅ ≥99% LC-MS Purity (Single Peak) ✅ Identity: ESI-MS [M+H]+ 291.1 ±0.1 Da ✅ Endotoxin: <0.1 EU/mg (LAL) ✅ Heavy Metals: <10 ppm (ICP-MS) ✅ Residual Solvents: USP <467> ✅ Microbial: USP <71> Sterile **Metabolic**: CLAMS (EE, RER, FAO), GTT/ITT, plasma lipids **Muscle**: Treadmill endurance, mtDNA, cyt-c, OXPHOS IHC **Liver**: Oil Red O, TG content, β-oxidation PCR panel **Gene PD**: ERRα targets (Ppargc1a, Cpt1b, Tfam, Ndufs4)